Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation

Pharmacology and Therapeutics

Volumn 142, Issue 3, 2014, Pages 351-361

  Wartha, K ^a   Herting, F ^a   Hasmann, M ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Cancer therapeutics; Drug evaluation; Mouse; Preclinical; Predictivity; Tumor models

Indexed keywords

BETA 2 MICROGLOBULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; INTERLEUKIN 2 RECEPTOR; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; IMMUNOLOGIC FACTOR;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER RADIOTHERAPY; CANCER THERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG SCREENING; GENETICALLY ENGINEERED MOUSE STRAIN; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENCE; MACROPHAGE; METASTASIS; MOUSE MODEL; MOUSE STRAIN; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROMA CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; GENETIC ENGINEERING; METHODOLOGY; MOUSE; NEOPLASMS; PRECLINICAL STUDY; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENETIC ENGINEERING; HUMANS; IMMUNOLOGIC FACTORS; MICE; MICE, TRANSGENIC; NEOPLASMS; RESEARCH DESIGN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898895657     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.01.001     Document Type: Review

References (74)

1. ASCO American society of clinical oncology Progress against cancer 2012 (http://www.cancer.net/sites/cancer.net/files/vignette/Progress-Against-Cancer- Timeline.pdf [On-line])
2. J. Baselga, J. Cortes, S.B. Kim, S.A. Im, R. Hegg, and Y.H. Im et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
3. J. Baselga, and S.M. Swain CLEOPATRA: A phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer Clin Breast Cancer 10 2010 489 491
4. G.L. Beatty, E.G. Chiorean, M.P. Fishman, B. Saboury, U.R. Teitelbaum, and W. Sun et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
5. J.S. Bertram, and P. Janik Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture Cancer Lett 11 1980 63 73 (Pubitemid 11198069)
6. P.D. Bos, D.X. Nguyen, and J. Massague Modeling metastasis in the mouse Curr Opin Pharmacol 10 2010 571 577
7. D. Burgos-Ojeda, K. McLean, S. Bai, H. Pulaski, Y. Gong, and I. Silva et al. A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells Cancer Res 73 2013 3555 3565
8. H.A. Burris III, H.S. Rugo, S.J. Vukelja, C.L. Vogel, R.A. Borson, and S. Limentani et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy J Clin Oncol 29 2011 398 405
9. M.K. Callahan, and J.D. Wolchok At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy J Leukoc Biol 94 2013 41 53
10. E. Chan, A. Patel, W. Heston, and W. Larchian Mouse orthotopic models for bladder cancer research BJU Int 104 2009 1286 1291
11. S. Cho, Y. Sun, A.P. Soisson, M.K. Dodson, C.M. Peterson, and E.A. Jarboe et al. Characterization and evaluation of pre-clinical suitability of a syngeneic orthotopic mouse ovarian cancer model Anticancer Res 33 2013 1317 1324
12. I. Daphu, T. Sundstrom, S. Horn, P.C. Huszthy, S.P. Niclou, and P.O. Sakariassen et al. In vivo animal models for studying brain metastasis: Value and limitations Clin Exp Metastasis 30 2013 695 710
13. G.M. de Jong, F. Aarts, T. Hendriks, O.C. Boerman, and R.P. Bleichrodt Animal models for liver metastases of colorectal cancer: Research review of preclinical studies in rodents J Surg Res 154 2009 167 176
14. R.M. De, E. Massi, M.L. Poeta, S. Carotti, S. Morini, and L. Cecchetelli et al. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies J Carcinog 10 2011 9
15. A.C. Drake, Q. Chen, and J. Chen Engineering humanized mice for improved hematopoietic reconstitution Cell Mol Immunol 9 2012 215 224
16. J.M. Ebos, and R.S. Kerbel Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis Nat Rev Clin Oncol 8 2011 210 221
17. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
18. C. Feig, A. Gopinathan, A. Neesse, D.S. Chan, N. Cook, and D.A. Tuveson The pancreas cancer microenvironment Clin Cancer Res 18 2012 4266 4276
19. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, and H. Comber et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403
20. I.J. Fidler Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment J Natl Cancer Inst 93 2001 1040 1041 (Pubitemid 32717529)
21. G. Francia, W. Cruz-Munoz, S. Man, P. Xu, and R.S. Kerbel Mouse models of advanced spontaneous metastasis for experimental therapeutics Nat Rev Cancer 11 2011 135 141
22. K.K. Frese, A. Neesse, N. Cook, T.E. Bapiro, M.P. Lolkema, and D.I. Jodrell et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer Cancer Discov 2 2012 260 269
23. C.A. Gerdes, V.G. Nicolini, S. Herter, P.E. Van, S. Lang, and M. Roemmele et al. GA201 (RG7160): A novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab Clin Cancer Res 19 2013 1126 1138
24. J.F. Grosso, and M.N. Jure-Kunkel CTLA-4 blockade in tumor models: An overview of preclinical and translational research Cancer Immun 13 2013 -5
25. D. Hanahan, G. Christofori, P. Naik, and J. Arbeit Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models Eur J Cancer 32A 1996 2386 2393
26. Y. Hayakawa, J.G. Fox, T. Gonda, D.L. Worthley, S. Muthupalani, and T.C. Wang Mouse models of gastric cancer Cancers 5 2013 92 130
27. F. Herting Antibodies to target cancer Preclinical assays in cancer therapy 2012 NKI-AVL Amsterdam
28. M. Hidalgo, E. Bruckheimer, N.V. Rajeshkumar, I. Garrido-Laguna, O.E. De, and B. Rubio-Viqueira et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer Mol Cancer Ther 10 2011 1311 1316
29. A.M. Intlekofer, and C.B. Thompson At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy J Leukoc Biol 94 2013 25 39
30. R. Ito, T. Takahashi, I. Katano, and M. Ito Current advances in humanized mouse models Cell Mol Immunol 9 2012 208 214
31. K.A. Keyes, L. Mann, B. Teicher, and E. Alvarez Site-dependent angiogenic cytokine production in human tumor xenografts Cytokine 21 2003 98 104 (Pubitemid 36369396)
32. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 2004 711 715 (Pubitemid 39173511)
33. G.D. Lewis Phillips, G. Li, D.L. Dugger, L.M. Crocker, K.L. Parsons, and E. Mai et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 2008 9280 9290
34. M. Loi, P.D. Di, P. Becherini, A. Zorzoli, P. Perri, and R. Carosio et al. The use of the orthotopic model to validate antivascular therapies for cancer Int J Dev Biol 55 2011 547 555
35. D.H. Lum, C. Matsen, A.L. Welm, and B.E. Welm Overview of human primary tumorgraft models: Comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research Curr Protoc Pharmacol 2012 10.1002/0471141755 (Chapter 14, Unit)
36. P. Malaney, S.V. Nicosia, and V. Dave One mouse, one patient paradigm: New avatars of personalized cancer therapy Cancer Lett 2013 10.1016/j.canlet. 2013.10.010
37. S.P. McDermott, K. Eppert, E.R. Lechman, M. Doedens, and J.E. Dick Comparison of human cord blood engraftment between immunocompromised mouse strains Blood 116 2010 193 200
38. J. Mestas, and C.C. Hughes Of mice and not men: Differences between mouse and human immunology J Immunol 172 2004 2731 2738 (Pubitemid 38263654)
39. C. Murdoch, M. Muthana, S.B. Coffelt, and C.E. Lewis The role of myeloid cells in the promotion of tumour angiogenesis Nat Rev Cancer 8 2008 618 631
40. T. Nomura, S. Habu, and T. Watanabe Humanized mice 2008 Springer-Verlag Berlin Heidelberg Berlin, Heidelberg
41. E. Ostermann, P. Garin-Chesa, K.H. Heider, M. Kalat, H. Lamche, and C. Puri et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts Clin Cancer Res 14 2008 4584 4592
42. P.D. Ottewell, R.E. Coleman, and I. Holen From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies Breast Cancer Res Treat 96 2006 101 113
43. W.W. Overwijk, and N.P. Restifo B16 as a mouse model for human melanoma Curr Protoc Immunol 2001 10.1002/0471142735 (Chapter 20, Unit)
44. K.H. Paraiso, and K.S. Smalley Fibroblast-mediated drug resistance in cancer Biochem Pharmacol 85 2013 1033 1041
45. K. Politi, and W. Pao How genetically engineered mouse tumor models provide insights into human cancers J Clin Oncol 29 2011 2273 2281
46. B.A. Pulaski, and S. Ostrand-Rosenberg Mouse 4T1 breast tumor model Curr Protoc Immunol 2001 10.1002/0471142735 (Chapter 20, Unit)
47. F. Reyal, C. Guyader, C. Decraene, C. Lucchesi, N. Auger, and F. Assayag et al. Molecular profiling of patient-derived breast cancer xenografts Breast Cancer Res 14 2012 R11
48. A. Rongvaux, H. Takizawa, T. Strowig, T. Willinger, E.E. Eynon, and R.A. Flavell et al. Human hemato-lymphoid system mice: Current use and future potential for medicine Annu Rev Immunol 31 2013 635 674
49. D.W. Rosenberg, C. Giardina, and T. Tanaka Mouse models for the study of colon carcinogenesis Carcinogenesis 30 2009 183 196
50. T.J. Rosol, S.H. Tannehill-Gregg, B.E. LeRoy, S. Mandl, and C.H. Contag Animal models of bone metastasis Cancer 97 2003 748 757 (Pubitemid 36125810)
51. D. Sano, and J.N. Myers Xenograft models of head and neck cancers Head Neck Oncol 1 2009 -32
52. M. Saxena, and G. Christofori Rebuilding cancer metastasis in the mouse Mol Oncol 7 2013 283 296
53. W. Scheuer, T. Friess, H. Burtscher, B. Bossenmaier, J. Endl, and M. Hasmann Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models Cancer Res 69 2009 9330 9336
54. T. Schneider, F. Osl, T. Friess, H. Stockinger, and W.V. Scheuer Quantification of human Alu sequences by real-time PCR - an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants Clin Exp Metastasis 19 2002 571 582 (Pubitemid 35454567)
55. E. Senkus, S. Kyriakides, F. Penault-Llorca, P. Poortmans, A. Thompson, and S. Zackrisson et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 24 Suppl. 6 2013 vi7 vi23
56. B. Sennino, T. Ishiguro-Oonuma, Y. Wei, R.M. Naylor, C.W. Williamson, and V. Bhagwandin et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors Cancer Discov. 2 2012 270 287
57. L.D. Shultz, F. Ishikawa, and D.L. Greiner Humanized mice in translational biomedical research Nat Rev Immunol 7 2007 118 130 (Pubitemid 46174859)
58. M. Singh, and N. Ferrara Modeling and predicting clinical efficacy for drugs targeting the tumor milieu Nat Biotechnol 30 2012 648 657
59. M. Singh, A. Lima, R. Molina, P. Hamilton, A.C. Clermont, and V. Devasthali et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models Nat Biotechnol 28 2010 585 593
60. M. Singh, C.L. Murriel, and L. Johnson Genetically engineered mouse models: Closing the gap between preclinical data and trial outcomes Cancer Res 72 2012 2695 2700
61. D. Siolas, and G.J. Hannon Patient-derived tumor xenografts: Transforming clinical samples into mouse models Cancer Res 73 2013 5315 5319
62. C.A. Staton, C. Lewis, and R. Bicknell Angiogenesis assays: A critical appraisal of current techniques 2007 (Wiley.com)
63. J.J. Tentler, A.C. Tan, C.D. Weekes, A. Jimeno, S. Leong, and T.M. Pitts et al. Patient-derived tumour xenografts as models for oncology drug development Nat Rev Clin Oncol 9 2012 338 350
64. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
65. M.P. Torres, S. Rachagani, J.J. Souchek, K. Mallya, S.L. Johansson, and S.K. Batra Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: Applications in diagnosis and therapy PLoS One 8 2013 e80580
66. W. Tseng, X. Leong, and E. Engleman Orthotopic mouse model of colorectal cancer J Vis Exp 2007 -484
67. T. Tsukamoto, T. Mizoshita, and M. Tatematsu Animal models of stomach carcinogenesis Toxicol Pathol 35 2007 636 648 (Pubitemid 47123741)
68. H.G. Vikis, A.L. Rymaszewski, and J.W. Tichelaar Mouse models of chemically-induced lung carcinogenesis Front Biosci (Elite Ed) 5 2013 939 946
69. A. Vonlaufen, S. Joshi, C. Qu, P.A. Phillips, Z. Xu, and N.R. Parker et al. Pancreatic stellate cells: Partners in crime with pancreatic cancer cells Cancer Res 68 2008 2085 2093 (Pubitemid 351521780)
70. 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies mAbs 6 2013 0 1 10.4161/mabs.27415
71. J.C. Walrath, J.J. Hawes, D.T. Van, and K.M. Reilly Genetically engineered mouse models in cancer research Adv Cancer Res 106 2010 113 164
72. H. Watanabe, K. Numata, T. Ito, K. Takagi, and A. Matsukawa Innate immune response in Th1- and Th2-dominant mouse strains Shock 22 2004 460 466 (Pubitemid 39472571)
73. C.B. Westphalen, and K.P. Olive Genetically engineered mouse models of pancreatic cancer Cancer J 18 2012 502 510
74. P.A. Zucali, M.G. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, and K. Floor et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors Ann Oncol 19 2008 1605 1612